Zura Bio (ZURA) Long-Term Debt Issuances (2023)

Zura Bio's (ZURA) quarterly Long-Term Debt Issuances came in at $10.0 million in Q1 2023.

Zura Bio (ZURA) Long-Term Debt Issuances (2023) Analysis & Trends

Zura Bio's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $10.0 million for Q1 2023.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million in Q1 2023; TTM through Dec 2023 was $10.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $10.0 million, up 31.58% from the prior year.
Long-Term Debt Issuances steadied at $10.0 million in Q1 2023 per ZURA's latest filing.
Across five years, Long-Term Debt Issuances topped out at $10.0 million in Q1 2023 and bottomed at $10.0 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Zura Bio	593.66 Mn	593.66 Mn	-	-

Download Data

Date	Value
Mar 31, 2023	10.00 Mn
Mar 31, 2023	10.00 Mn